Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$8.81M
• Dividend Yield: N/A
• Average Volume (3M): 82.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -48.33%
• EPS Growth: 47.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 72
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 92,814
• 30 Day Avg. Volume: 82,620
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 340.99
• Price to Cash Flow (P/CF): -3.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Mountain Valley MD's overall stock score is primarily impacted by its severe financial challenges, including consistent losses and negative cash flows, despite having no debt. The technical analysis offers some short-term optimism with prices above key moving averages, but the valuation remains unattractive due to a negative P/E ratio and absence of dividends. These factors collectively result in a low overall score, highlighting the risks associated with the stock.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD (MVMD) is a biopharmaceutical company focused on the development and commercialization of health and wellness products. The company operates primarily in the sectors of life sciences and biotechnology, with a core emphasis on advanced delivery technologies for vaccines, drugs, and nutraceuticals. MVMD aims to enhance the efficacy and accessibility of medical treatments through its pioneering Quicksome™ and Quicksol™ technologies, which are designed to improve the bioavailability and stability of active ingredients.

How the Company Makes Money

Mountain Valley MD generates revenue through the licensing and commercialization of its proprietary drug delivery technologies, Quicksome™ and Quicksol™. The company partners with pharmaceutical and nutraceutical firms to integrate these technologies into their products, enhancing their performance and marketability. Revenue streams include licensing fees, royalties from product sales, and potentially milestone payments from partners. MVMD may also pursue direct sales of its own branded health products utilizing its technology. Strategic partnerships and collaborations with industry leaders play a significant role in expanding its market reach and driving earnings growth.

Mountain Valley MD Financial Statement Overview

Summary

Mountain Valley MD faces significant financial challenges, characterized by consistent losses, decreasing revenues, and negative cash flows. While the company benefits from a debt-free capital structure, the lack of profitability and cash generation poses substantial risks to its financial health. Continued focus on improving revenue streams and cost management is crucial for future stability.

Income Statement

Mountain Valley MD shows a concerning trend in its income statement with persistently negative net and gross profit margins. The TTM data indicates a gross loss and a significant net loss relative to revenues, suggesting challenges in revenue generation and cost management. Revenue growth has been erratic, with a decline from the previous annual report, indicating instability in business operations.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, which is a positive aspect in terms of financial stability. However, the declining asset base and stockholders' equity over time raise concerns about the company's ability to sustain operations and growth. The equity ratio remains favorable, but the overall financial health is at risk if operational losses continue.

Cash Flow

The cash flow statement highlights significant negative free cash flow and operating cash flow, indicating liquidity issues and challenges in covering operational expenses. The absence of debt is a positive factor, but the consistent cash outflows could constrain future investments and operational scalability.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
31.00K	60.00K	0.00	110.00K	0.00	0.00
	Gross Profit
-81.00K	-346.00K	-446.00K	70.00K	-430.19K	-52.16K
	EBIT
-2.22M	-3.19M	-3.50M	-9.74M	-5.28M	-3.23M
	EBITDA
-3.41M	-3.19M	-6.89M	-9.29M	-7.57M	-18.51M
	Net Income Common Stockholders
-4.01M	-7.67M	-7.44M	-9.71M	-8.14M	-18.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.36M	5.92M	9.71M	14.22M	19.51M	1.74M
	Total Assets
7.74M	8.97M	16.77M	25.27M	31.61M	12.23M
	Total Debt
0.00	0.00	6.00K	44.00K	84.50K	553.24K
	Net Debt
-2.36M	-5.92M	-9.71M	-14.18M	-19.43M	-1.19M
	Total Liabilities
108.00K	258.00K	591.00K	422.00K	1.11M	3.68M
	Stockholders Equity
7.63M	8.71M	16.18M	24.85M	30.50M	8.55M
Cash Flow		Free Cash Flow
-4.22M	-3.80M	-4.85M	-5.68M	-4.31M	-3.74M
	Operating Cash Flow
-4.21M	-3.30M	-4.79M	-5.59M	-3.86M	-2.98M
	Investing Cash Flow
-276.00K	-503.00K	1.89M	-98.00K	-149.32K	-6.00M
	Financing Cash Flow
-6.00K	0.00	-1.60M	395.00K	21.78M	1.63M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.53 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
BCT	42 Neutral	C$21.03M	―	-478.64%	―	―	56.78%
MVMD	38 Underperform	C$8.81M	―	-44.58%	―	-48.33%	47.56%
SVA	33 Underperform	C$49.27M	―	248.46%	―	―	32.71%
HBP	33 Underperform	C$42.42M	―	685.26%	―	―	-50.29%

Mountain Valley MD Corporate Events

Mountain Valley MD Advances Commercialization Strategies

Mountain Valley MD Holdings Inc. has advanced its commercialization strategies across its nutraceutical, agriculture, and husbandry animal sectors, aiming to enhance product efficacy and market reach. The company has strengthened its manufacturing and distribution partnerships, setting the stage for continued growth and increased revenues in 2025.